Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7906 to 7920 of 8896 results

  1. Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (TA150)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 242.

    Withdrawn guidance

  2. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  3. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  4. Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents (TA13)

    This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].  

    Withdrawn guidance

  5. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  6. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  7. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

    Withdrawn guidance

  8. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  9. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  10. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Withdrawn guidance

  11. Infliximab for subacute manifestations of ulcerative colitis (TA140)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance

  12. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  13. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Withdrawn guidance

  14. Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

    This guidance has been updated and replaced by NICE guideline NG156.

    Withdrawn guidance

  15. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105. 

    Withdrawn guidance